GuidelineCancer treatment reviews2018
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).
Guideline in Cancer treatment reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04577495 (Correlation of CT Scan Parameters With Histology, Stage and Prognosis in Surgically-treated Thymomas), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation of CT Scan Parameters With Histology, Stage and Prognosis in Surgically-treated Thymomas
Who cites it
33 citing papers in PubMed.
- A multiparameter diagnostic model based on MRI volumetric ADC histogram and clinical variables accurately differentiates thymic epithelial tumors from mediastinal lymphomas.BMC medical imaging · 2026Article
- Thymic tumors: radiotherapy experience for single institute.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- CD55 may be an important prognostic factor of thymic epithelial tumors: a retrospective study.World journal of surgical oncology · 2025Article
- Treatment of thymoma with low-dose glucocorticoids before surgery for significant tumor shrinkage: A case report.World journal of clinical cases · 2025Article
- Spleen metastasis as rare systemic manifestation of thymoma: a case report.Mediastinum (Hong Kong, China) · 2025Article
- When rarity meets thoracic cancers: a narrative review from ITMIG 2024.Mediastinum (Hong Kong, China) · 2025Review
- The Prognostic Role of the Number of Involved Structures in Thymic Epithelial Tumors: Results from the ESTS Database.Annals of surgical oncology · 2024Article
- Article
- Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor.Frontiers in immunology · 2024Article
- Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.Frontiers in immunology · 2024Review
- Review
- Immunologic Significance of CD80/CD86 or Major Histocompatibility Complex-II Expression in Thymic Epithelial Tumors.JTO clinical and research reports · 2023Article
- Prognostic factors and role of postoperative radiotherapy in surgically resected thymomas.JTCVS open · 2023Article
- Pediatric Thymoma: A Review and Update of the Literature.Diagnostics (Basel, Switzerland) · 2022Review
- Pathological tumor long-to-short axis ratio as a prognostic factor in patients with thymic epithelial tumors.Thoracic cancer · 2022Article
- Computed Tomography-Based Radiomics for Differentiation of Thymic Epithelial Tumors and Lymphomas in Anterior Mediastinum.Frontiers in oncology · 2022Article
- Thymic tumours and their special features.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Characteristics of genomic mutations and signaling pathway alterations in thymic epithelial tumors.Annals of translational medicine · 2021Article
- GOECP/SEOR radiotherapy guidelines for thymic epithelial tumours.World journal of clinical oncology · 2021Review
- Induction Strategy for Locally Advanced Thymoma.Frontiers in oncology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic epithelial tumors (TETs) are a heterogenous group of rare tumors, with a complex histopatological classification. Furthermore, the recent introduction of the first TNM staging system, that is scheduled to replace the Masaoka-Koga system, may create further difficulties in TET management, that remains challenging. Several guidelines for treatment of TETs are available and provide recommendations based mainly on non randomized trials and retrospective or limited series. Often the lack of evidence leads to formulation of indications based on expert opinions. As for other rare cancers it is crucial to create networks to coordinate the work among centres involved in treatment of these diseases in order to offer the best diagnostic and therapeutic tools. For this purpose, in 2014 a network named TYME (ThYmic MalignanciEs), was founded in Italy with the aim of improving care and research in TETs. In September 2017 a panel of multidisciplinary experts from TYME network and from other Italian centres strongly involved in TET diagnosis and treatment convened a first Italian Expert meeting together with representatives of association for patients affected by rare thoracic cancers Tu.To.R, to explore how these tumors are managed in the different centres of Italy compared to ESMO guidelines. In this paper we summarize the issues discussed during that meeting and we propose recommandations based on Masaoka Koga and the new TNM staging system.
Indexed as
Identifiers
30366202What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.